Abatacept, previously known as CTLA4-Ig, is a recombinant human fusion protein comprising the extracellular domain of human CTLA4 along with the Fc piece of a human IgG1 molecule. CTLA4 is a naturally occurring inhibitor molecule that binds to CD80 and CD86 on antigen-presenting cells, thereby inhibiting the ability of CD28 to bind to these molecules and provide an activating signal. It is administered intravenously once per month and is approved for use in RA (Kremer et al. 2003). A Phase II trial for psoriasis has been conducted (Abrams et al. 1999). It is anticipated that further assessment of this drug will be conducted for PsA and for psoriasis.
Was this article helpful?
Do You Suffer From the Itching and Scaling of Psoriasis? Or the Chronic Agony of Psoriatic Arthritis? If so you are not ALONE! A whopping three percent of the world’s populations suffer from either condition! An incredible 56 million working hours are lost every year by psoriasis sufferers according to the National Psoriasis Foundation.